Provided by Tiger Trade Technology Pte. Ltd.

GENSCRIPT BIO

40.700
-2.200-5.13%
Volume:74.72M
Turnover:3.11B
Market Cap:92.96B
PE:-21.10
High:43.660
Open:42.880
Low:40.400
Close:42.900
52wk High:49.460
52wk Low:10.360
Shares:2.28B
HK Float Shares:2.28B
Volume Ratio:3.41
T/O Rate:3.27%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.929
ROE:-15.33%
ROA:1.54%
PB:3.05
PE(LYR):-21.10
PS:14.02

Loading ...

Movement Alert|Genscript Biotech Rises 5.04% in Regular Trading, CXO Sector Interim Results Beat Expectations Driving Sector Momentum

Market Focus
·
Jul 15

Movement Alert|Genscript Biotech Rises 5.27% in Regular Trading, CXO Sector Mid-Year Earnings Window Continues to Catalyze

Market Focus
·
Jul 13

Movement Alert|Genscript Biotech Rises 5.38% in Regular Trading, CXO Sector Rallies as Mid-Year Earnings Window Opens with Policy Tailwinds

Market Focus
·
Jul 10

Movement Alert|GenScript Biotech Rises 5.07% in Regular Trading, AI Drug Discovery Theme Drives Sector-Wide Rally

Market Focus
·
Jul 06

Movement Alert|Genscript Biotech Rises 6.46% in Regular Trading, Trading at HK$13.14

Market Focus
·
Jul 02

Hong Kong Market Midday Update: Hang Seng Index Edges Up, Chip Stocks Lead Gains

Stock News
·
Jun 24

CRO Sector Stocks Show Robust Gains in Early Trading Session

Deep News
·
Jun 24

Contract Research Organization Stocks Surge as BIO Conference Highlights Chinese CXO Global Competitiveness; Pharmaceutical Sector Openness Achieves New Milestone

Stock News
·
Jun 24

Movement Alert|GenScript Biotech Rises 5.34% in Regular Trading, Technical Recovery After Legend Biotech-Driven Selloff

Market Focus
·
Jun 24

Movement Alert|GenScript Biotech Falls 8.14% in Regular Trading, Associate Legend Biotech US Stock Plunge Drags Share Price

Market Focus
·
Jun 22

BUZZ-Legend Biotech slides on $226 mln share sale

Reuters
·
Jun 18

Movement Alert|GenScript Biotech Rises 5.41% in Regular Trading, Recovering After Legend Biotech LB2501 Clinical Data Triggered Sell-the-News Pullback

Market Focus
·
Jun 18

Genscript Associate Reports Promising Phase 1 Data for LB2501 in B-Cell Lymphoma

MT Newswires Live
·
Jun 15

Genscript Biotech Share Price Plummets Despite Positive Trial Results from Associate Company

Stock News
·
Jun 15

Movement Alert|GenScript Biotech Falls 6.07% in Regular Trading, CXO Sector Sentiment Remains Fragile Amid US-China Biomedical Policy Uncertainty

Market Focus
·
Jun 15

GenScript Biotech: Associate Legend Achieves 100% ORR with First-in-Class Dual-Targeting CAR-T LB2501 in Early B-NHL Trial

Bulletin Express
·
Jun 14

Genscript Biotech's Affiliate Reports Proof of Concept for Novel In Vivo Dual-Target CAR-T Therapy in Lymphoma

Stock News
·
Jun 14

GenScript says associate Legend posts Phase 1 proof-of-concept data for LB2501 in vivo CD19/CD20 CAR-T in R/R B-cell lymphoma

Reuters
·
Jun 14

Movement Alert|GenScript Biotech Rises 5.07% in Regular Trading, Legend Biotech In-Vivo CAR-T Data Presented at EHA Conference

Market Focus
·
Jun 12

Movement Alert|GenScript Biotech Falls 5.05% in Regular Trading, CXO Sector Under Sustained Pressure Amid US Investment Restriction Concerns

Market Focus
·
Jun 09